PIK3CA and Proteus syndrome: Miransertib was initially used to treat human malignant tumours, but in recent years it has primarily been used to treat a variety of rare disorders, including PIK3CA-related overgrowth spectrum caused by somatic activating mutations in PIK3CA and Proteus syndrome caused by somatic activation in AKT1255,.269